In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis

Guodong Cao, Wei Pei, Hailiang Ge, Qinhua Liang, Yumin Luo, Frank R Sharp, Aigang Lu, Ruiqiong Ran, Steven H. Graham, Jun Chen

Research output: Contribution to journalArticle

368 Citations (Scopus)

Abstract

Bcl-xL is a well characterized death-suppressing molecule of the Bcl-2 family. Bcl-xL is expressed in embryonic and adult neurons of the CNS and may play a critical role in preventing neuronal apoptosis that occurs during brain development or results from diverse pathologic stimuli, including cerebral ischemia. In this study, we used a novel approach to study the potential neuroprotective effect of Bcl-xL as a therapeutic agent in the murine model of focal ischemia/reperfusion. We created a Bcl-xL fusion protein, designated as PTD-HA-Bcl-xL, which contains the protein transduction domain (PTD) derived from the human immunodeficiency TAT protein. We demonstrated that this fusion protein is highly efficient in transducing into primary neurons in cultures and potently inhibited staurosporin-induced neuronal apoptosis. Furthermore, intraperitoneal injection of PTD-HA-Bcl-xL into mice resulted in robust protein transduction in neurons in various brain regions within 1-2 hr, and decreased cerebral infarction (up to ∼40%) in a dose-dependent manner, as determined at 3 d after 90 min of focal ischemia. PTD-HA-Bcl-xL was effective even when it was administered after the completion of ischemia (up to 45 min), and the protective effect was independent of the changes in cerebral blood flow or other physiological parameters. Finally, as shown by immunohistochemistry, Western blotting, and substrate-cleavage assays, PTD-HA-Bcl-xL attenuated ischemia-induced caspase-3 activation in ischemic neurons. These results thus confirm the neuroprotective effect of Bcl-xL against ischemic brain injury and provide the first evidence that the PTD can be used to efficiently transduce a biologically active neuroprotectant in experimental cerebral ischemia.

Original languageEnglish (US)
Pages (from-to)5423-5431
Number of pages9
JournalJournal of Neuroscience
Volume22
Issue number13
StatePublished - Jul 1 2002
Externally publishedYes

Fingerprint

Brain Injuries
Apoptosis
Neuroprotective Agents
Ischemia
Neurons
Proteins
Brain Ischemia
Cerebrovascular Circulation
Cerebral Infarction
Brain
Intraperitoneal Injections
Caspase 3
Reperfusion
Protein Domains
Western Blotting
Immunohistochemistry

Keywords

  • Bcl-2
  • Caspase-3, cytochrome c
  • Cerebral ischemia
  • Protein transduction
  • Stroke

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. / Cao, Guodong; Pei, Wei; Ge, Hailiang; Liang, Qinhua; Luo, Yumin; Sharp, Frank R; Lu, Aigang; Ran, Ruiqiong; Graham, Steven H.; Chen, Jun.

In: Journal of Neuroscience, Vol. 22, No. 13, 01.07.2002, p. 5423-5431.

Research output: Contribution to journalArticle

Cao, Guodong ; Pei, Wei ; Ge, Hailiang ; Liang, Qinhua ; Luo, Yumin ; Sharp, Frank R ; Lu, Aigang ; Ran, Ruiqiong ; Graham, Steven H. ; Chen, Jun. / In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. In: Journal of Neuroscience. 2002 ; Vol. 22, No. 13. pp. 5423-5431.
@article{9c99b3589c3c40cdbd8550976fc26b1b,
title = "In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis",
abstract = "Bcl-xL is a well characterized death-suppressing molecule of the Bcl-2 family. Bcl-xL is expressed in embryonic and adult neurons of the CNS and may play a critical role in preventing neuronal apoptosis that occurs during brain development or results from diverse pathologic stimuli, including cerebral ischemia. In this study, we used a novel approach to study the potential neuroprotective effect of Bcl-xL as a therapeutic agent in the murine model of focal ischemia/reperfusion. We created a Bcl-xL fusion protein, designated as PTD-HA-Bcl-xL, which contains the protein transduction domain (PTD) derived from the human immunodeficiency TAT protein. We demonstrated that this fusion protein is highly efficient in transducing into primary neurons in cultures and potently inhibited staurosporin-induced neuronal apoptosis. Furthermore, intraperitoneal injection of PTD-HA-Bcl-xL into mice resulted in robust protein transduction in neurons in various brain regions within 1-2 hr, and decreased cerebral infarction (up to ∼40{\%}) in a dose-dependent manner, as determined at 3 d after 90 min of focal ischemia. PTD-HA-Bcl-xL was effective even when it was administered after the completion of ischemia (up to 45 min), and the protective effect was independent of the changes in cerebral blood flow or other physiological parameters. Finally, as shown by immunohistochemistry, Western blotting, and substrate-cleavage assays, PTD-HA-Bcl-xL attenuated ischemia-induced caspase-3 activation in ischemic neurons. These results thus confirm the neuroprotective effect of Bcl-xL against ischemic brain injury and provide the first evidence that the PTD can be used to efficiently transduce a biologically active neuroprotectant in experimental cerebral ischemia.",
keywords = "Bcl-2, Caspase-3, cytochrome c, Cerebral ischemia, Protein transduction, Stroke",
author = "Guodong Cao and Wei Pei and Hailiang Ge and Qinhua Liang and Yumin Luo and Sharp, {Frank R} and Aigang Lu and Ruiqiong Ran and Graham, {Steven H.} and Jun Chen",
year = "2002",
month = "7",
day = "1",
language = "English (US)",
volume = "22",
pages = "5423--5431",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "13",

}

TY - JOUR

T1 - In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis

AU - Cao, Guodong

AU - Pei, Wei

AU - Ge, Hailiang

AU - Liang, Qinhua

AU - Luo, Yumin

AU - Sharp, Frank R

AU - Lu, Aigang

AU - Ran, Ruiqiong

AU - Graham, Steven H.

AU - Chen, Jun

PY - 2002/7/1

Y1 - 2002/7/1

N2 - Bcl-xL is a well characterized death-suppressing molecule of the Bcl-2 family. Bcl-xL is expressed in embryonic and adult neurons of the CNS and may play a critical role in preventing neuronal apoptosis that occurs during brain development or results from diverse pathologic stimuli, including cerebral ischemia. In this study, we used a novel approach to study the potential neuroprotective effect of Bcl-xL as a therapeutic agent in the murine model of focal ischemia/reperfusion. We created a Bcl-xL fusion protein, designated as PTD-HA-Bcl-xL, which contains the protein transduction domain (PTD) derived from the human immunodeficiency TAT protein. We demonstrated that this fusion protein is highly efficient in transducing into primary neurons in cultures and potently inhibited staurosporin-induced neuronal apoptosis. Furthermore, intraperitoneal injection of PTD-HA-Bcl-xL into mice resulted in robust protein transduction in neurons in various brain regions within 1-2 hr, and decreased cerebral infarction (up to ∼40%) in a dose-dependent manner, as determined at 3 d after 90 min of focal ischemia. PTD-HA-Bcl-xL was effective even when it was administered after the completion of ischemia (up to 45 min), and the protective effect was independent of the changes in cerebral blood flow or other physiological parameters. Finally, as shown by immunohistochemistry, Western blotting, and substrate-cleavage assays, PTD-HA-Bcl-xL attenuated ischemia-induced caspase-3 activation in ischemic neurons. These results thus confirm the neuroprotective effect of Bcl-xL against ischemic brain injury and provide the first evidence that the PTD can be used to efficiently transduce a biologically active neuroprotectant in experimental cerebral ischemia.

AB - Bcl-xL is a well characterized death-suppressing molecule of the Bcl-2 family. Bcl-xL is expressed in embryonic and adult neurons of the CNS and may play a critical role in preventing neuronal apoptosis that occurs during brain development or results from diverse pathologic stimuli, including cerebral ischemia. In this study, we used a novel approach to study the potential neuroprotective effect of Bcl-xL as a therapeutic agent in the murine model of focal ischemia/reperfusion. We created a Bcl-xL fusion protein, designated as PTD-HA-Bcl-xL, which contains the protein transduction domain (PTD) derived from the human immunodeficiency TAT protein. We demonstrated that this fusion protein is highly efficient in transducing into primary neurons in cultures and potently inhibited staurosporin-induced neuronal apoptosis. Furthermore, intraperitoneal injection of PTD-HA-Bcl-xL into mice resulted in robust protein transduction in neurons in various brain regions within 1-2 hr, and decreased cerebral infarction (up to ∼40%) in a dose-dependent manner, as determined at 3 d after 90 min of focal ischemia. PTD-HA-Bcl-xL was effective even when it was administered after the completion of ischemia (up to 45 min), and the protective effect was independent of the changes in cerebral blood flow or other physiological parameters. Finally, as shown by immunohistochemistry, Western blotting, and substrate-cleavage assays, PTD-HA-Bcl-xL attenuated ischemia-induced caspase-3 activation in ischemic neurons. These results thus confirm the neuroprotective effect of Bcl-xL against ischemic brain injury and provide the first evidence that the PTD can be used to efficiently transduce a biologically active neuroprotectant in experimental cerebral ischemia.

KW - Bcl-2

KW - Caspase-3, cytochrome c

KW - Cerebral ischemia

KW - Protein transduction

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0036663014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036663014&partnerID=8YFLogxK

M3 - Article

C2 - 12097494

AN - SCOPUS:0036663014

VL - 22

SP - 5423

EP - 5431

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 13

ER -